A study involving hospitalized adults today in JAMA Network Open finds that severe COVID-19 negatively affects brain health, but no more so than pneumonia, heart attack, or other critical illnesses.
A new report published in Open Forum Infectious Diseases demonstrates that, despite the proven effectiveness of Paxlovid and molnupiravir against severe COVID-19 outcomes, uptake of these two antivirals remains low among Americans with COVID.
Recent Comments